Europe's Patchwork Approach to Biliary Atresia Screening: From Color Cards to AI-Powered Solutions

Europe's Fragmented Approach to Biliary Atresia Screening

A groundbreaking scoping review published in the World Journal of Pediatric Surgery on May 12, 2025, has shed light on the disparate approaches to biliary atresia (BA) screening across Europe 1

1

. Researchers from Geneva University Hospitals conducted the first comprehensive assessment of BA screening efforts, revealing a patchwork landscape that highlights both systemic challenges and promising technological advancements.

Current Screening Strategies

The review examined three major screening strategies: stool color cards (SCC), serum bilirubin testing, and biochemical profiling. Switzerland emerged as a pioneer, being the first European country to implement a national SCC program, which successfully reduced the median age of surgery for BA patients 1

1

. France and Germany have since followed suit, with Germany recently mandating nationwide SCC use.

However, the adoption of screening methods remains sporadic in many other European countries. The effectiveness of SCC programs is significantly enhanced when accompanied by clear referral guidelines, yet resistance persists among some pediatricians due to concerns about workload and psychological impact on parents 2

2

.

Technological Advancements and AI Integration

Recent technological breakthroughs are showing strong potential for improving the accuracy and scalability of BA screening:

1. Italy's PopòApp: A digital application designed to assist in stool color assessment 1

   1

   .
2. Germany's AI-powered stool image analysis: Utilizing artificial intelligence to enhance diagnostic accuracy 1

   1

   .

These innovations represent a shift from traditional methods to more sophisticated, AI-driven approaches that could revolutionize early diagnosis for thousands of infants.

Challenges and Opportunities

Despite the availability of expertise, evidence, and technology, Europe faces significant challenges in implementing widespread BA screening. The United Kingdom, for instance, has conducted extensive research on bilirubin screening, demonstrating exceptional accuracy. However, the transition from research to policy has been hindered by logistical and financial barriers 2

2

.

Professor Barbara E. Wildhaber, senior author of the study, emphasizes the urgency of the situation: "Europe has no shortage of expertise, evidence, or technology -- what's missing is coordinated action. We've seen how something as simple as a color card can shift outcomes dramatically. Add digital tools and clinical buy-in, and we could revolutionize early diagnosis for thousands of infants. But time is of the essence -- each delay costs lives." 1

1

The Path Forward

The review advocates for a unified European strategy to combat BA-related infant mortality. Key recommendations include:

1. Combining SCC with digital apps and AI to provide low-cost, high-reach solutions.
2. Integrating serum bilirubin testing to capture a wider spectrum of liver diseases.
3. Developing hybrid screening models tailored to each country's healthcare infrastructure.
4. Pairing technical rollouts with education, awareness campaigns, and strong political advocacy 2

   2

   .

By aligning tools, policy, and public will, Europe has the potential to significantly improve early diagnosis and treatment of biliary atresia, ultimately saving infant lives and reducing long-term health complications.